Advances in molecular imaging for the diagnosis of dementia

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 6, 2009, Pages 705-716

  Okamura, Nobuyuki ^a   Fodero Tavoletti, Michelle T ^d   Kudo, Yukitsuka ^a   Rowe, Christopher C ^b   Furumoto, Shozo ^a   Arai, Hiroyuki ^a   Masters, Colin L ^c   Yanai, Kazuhiko ^a   Villemagne, Victor L ^b,c  

^a TOHOKU UNIVERSITY   (Japan)

^b AUSTIN HEALTH   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid protein; Dementia; Imaging; Molecular imaging; Near infrared; Positron emission tomography; Prion; Single photon emission computed tomography; Tau

Indexed keywords

2 [1 [6 (2 FLUOROETHYLMETHYLAMINO) 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YL)ETHENYL] 6 [2 (FLUORO)ETHOXY]BENZOXAZOLE C 11; 4 (N METHYLAMINO) 4' [2 [2 (2 FLUOROETHOXY)ETHOXY]ETHOXY]STILBENE F 18; 4 N METHYLAMINO 4' HYDROXYSTILBENE C 11; ALPHA SYNUCLEIN; AMYLOID; BAY 94 9172; BF 227; CARBON 11; FLUORINE 18; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; PRION PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DRUG STRUCTURE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MOLECULAR IMAGING; NEUROTRANSMISSION; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FOLDING; REVIEW;

EID: 77951810268     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050903133790     Document Type: Review

References (100)

1. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early AD. Ann Neurol 1997;42:85-94
2. Matsuda H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 2007;48:1289-1300
3. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002;43:21-26
4. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758
5. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127
6. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
7. McKeith I, Mintzer J, Aarsland D, et al. International psychogeriatric association expert meeting on DLB: Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28
8. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-325
9. Hanyu H, Shimizu S, Hirao K, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using mini-mental state examination and brain perfusion SPECT. J Neurol Sci 2006;250:97-102
10. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008;49:390-398
11. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130:2616-2635
12. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med 2006;47:302-312
13. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008;7:161-172
14. Bohnen NI, Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007;9:243-257
15. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126
16. Fishman EB, Siek GC, MacCallum RD, et al. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol 1986;19:246-252
17. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile. dementia BMJ 1978;25:1457-1459
18. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;30:408-414
19. Giacobini E. Cholinesterases and cholinesterase inhibitors. London: Taylor & Francis Group, 2000
20. Kilbourn MR, Snyder SE, Sherman PS, et al. In vivo studies of acetylcholinesterase activity using a labeled substrate, n-[C-11]methylpiperdin- 4-yl propionate ([C-11]PMP). Synapse 1996;22:123-131
21. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-1809
22. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699
23. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009:doi:10.1212/WNL.0b013e3181ab2b58
24. Sugimoto H, Ogura H, Arai Y, et al. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.Jpn J Pharmacol 2002;89:7-20
25. Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 2008;65:472-479
26. Shinotoh H, Aotsuka A, Fukushi K, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001;56:408-410
27. Villemagne VL, Musachio JL, Scheffel U. Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. New York: John Wiley & Sons, 1998
28. Nordberg A, Hartvig P, Lilja A, et al. Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography. Acta Radiol Suppl 1991;376:165-166
29. Horti AG, Villemagne VL. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des 2006;12:3877-3900
30. Ellis JR, Villemagne VL, Nathan PJ, et al. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem 2008;90:404-412
31. Koch HJ, Haas S, Jurgens T. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease. Curr Med Chem 2005;12:2915-2921
32. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007;6:721-733
33. Eckelman WC. Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des 2006;12:3901-3913
34. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-325
35. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925
36. Hu XS, Okamura N, Arai H, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000;55:1575-1577
37. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 2008;35(Suppl 1):S51-7
38. Watanabe H, Ieda T, Katayama T, et al. Cardiac 123I-meta- iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:781-783
39. Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-1854
40. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006;80:308-322
41. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461-467
42. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008;32:412-419
43. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72:56-62
44. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009;66:60-67
45. Doorduin J, de Vries EF, Dierckx RA, et al. PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des 2008;14:3297-3315
46. Vickers JC, Dickson TC, Adlard PA, et al. The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol 2000;60:139-165
47. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356
48. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999;45:358-368
49. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 2006;129:2823-2839
50. Villemagne VL, Ng S, Cappai R, et al. La Lunga Attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. Neuroradiol J 2006;19:51-75
51. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995;16:541-548
52. Skovronsky DM, Zhang B, Kung MP, et al. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.Proc Natl Acad Sci USA 2000;97:7609-7614
53. Zhuang ZP, Kung MP, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001;44:1905-1914
54. Link CD, Johnson CJ, Fonte V, et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 2001;22:217-226
55. Klunk WE, Bacskai BJ, Mathis CA, et al. Imaging Aß plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropath Exp Neurol 2002;61:797-805
56. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189
57. Barrio JR, Kepe V, Satyamurthy N, et al. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Aging 2008;12:61S-5S
58. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-6359.
59. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009;50:191-197
60. Shin J, Lee SY, Kim SH, et al. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008;43:236-244
61. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4?- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092
62. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754
63. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (A?) peptide-related cerebral amyloidosis. Brain 2007;130:2607-2615
64. Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007;27:10957-10968
65. Harigaya Y, Saido TC, Eckman CB, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 2000;276:422-427
66. Fodero-Tavoletti MT, Smith DP, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007;27:10365-10371
67. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547
68. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959-1972
69. McNamee RL, Yee SH, Price JC, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009;50:348-355
70. Fazio F, Perani D. Importance of partial-volume correction in brain PET studies. J Nucl Med 2000;41:1849-1850
71. Lowe J, Kemp BJ, Jack CR Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878-886
72. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319
73. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725
74. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434
75. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645
76. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304-1309
77. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910
78. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234
79. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145-147
80. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol 2006;59:512-519
81. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717
82. Nelissen N, Vandenbulcke M, Fannes K, et al. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007;130:2055-2069
83. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452
84. Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008;46:1688-1697
85. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008;43:430-439
86. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465
87. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680
88. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866
89. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501-508
90. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365
91. Zhuang ZP, Kung MP, Wilson A, et al. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting ?-amyloid plaques in the brain. J Med Chem 2003;46:237-243
92. Ono M, Wilson A, Nobrega J, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003;30:565-571
93. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-595
94. Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 2004;24:2535-2541 (Pubitemid 38327966)
95. Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007;48:553-561
96. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-135
97. Okamura N, Suemoto T, Furumoto S, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 2005;25:10857-10862
98. Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 2007;69:283-290
99. Villemagne VL, McLean CA, Reardon K, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009: doi:10.1136/jnnp.2008.171496
100. Hintersteiner M, Enz A, Frey P, et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005;23:577-583